Cantor Fitzgerald Weighs in on Radius Health Inc’s FY2017 Earnings (RDUS)

Radius Health Inc (NASDAQ:RDUS) – Cantor Fitzgerald lowered their FY2017 EPS estimates for Radius Health in a research note issued on Thursday. Cantor Fitzgerald analyst M. Goldstein now forecasts that the biopharmaceutical company will post earnings per share of ($5.30) for the year, down from their previous estimate of ($5.05). Cantor Fitzgerald currently has a “Buy” rating and a $58.00 price target on the stock.

A number of other analysts have also recently weighed in on RDUS. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a report on Friday, October 6th. Jefferies Group reduced their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. Radius Health currently has an average rating of “Hold” and a consensus target price of $49.86.

Shares of Radius Health (NASDAQ:RDUS) opened at $39.40 on Monday. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. The firm has a market capitalization of $1,760.00, a P/E ratio of -7.26 and a beta of 1.10.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm earned ($1.07) earnings per share.

A number of institutional investors have recently added to or reduced their stakes in RDUS. Cubist Systematic Strategies LLC purchased a new position in Radius Health during the third quarter worth $110,000. Ameritas Investment Partners Inc. grew its position in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 541 shares during the period. Advisor Group Inc. grew its position in shares of Radius Health by 267.2% in the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,888 shares during the period. Amalgamated Bank purchased a new stake in shares of Radius Health in the second quarter valued at $211,000. Finally, Principal Financial Group Inc. grew its position in shares of Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 839 shares during the period.

In other news, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $28.09 per share, with a total value of $49,944.02. Following the purchase, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jesper Hoiland acquired 6,800 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was purchased at an average cost of $29.04 per share, with a total value of $197,472.00. Following the completion of the purchase, the insider now directly owns 12,900 shares in the company, valued at $374,616. The disclosure for this purchase can be found here. Insiders purchased a total of 108,578 shares of company stock valued at $3,017,416 over the last ninety days. 15.00% of the stock is currently owned by company insiders.

WARNING: “Cantor Fitzgerald Weighs in on Radius Health Inc’s FY2017 Earnings (RDUS)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/24/cantor-fitzgerald-weighs-in-on-radius-health-incs-fy2017-earnings-rdus.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit